Symptomatic improvement after AV nodal ablation and pacemaker implantation for refractory atrial fibrillation and atrial flutter

Soo G. Kim, Vineel Sompalli, Anuradha Rameneni, Murali K. Gadde, Madhavi Pamidi, Raja Pathapati, Kevin J. Ferrick, Jay N. Gross, Uri Ben-Zur, Seymour Furman, John Devens Fisher

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Symptomatic Improvement was evaluated in 64 patients with drug- refractory atrial fibrillation or atrial flutter who underwent atrioventricular (AV) nodal ablation and permanent pacemaker implantation. The arrhythmias were chronic in 40 patients and paroxysmal in 24 patients. All were refractory to multiple drugs (3.7 ± 1.5) and had severe symptoms: palpitations (58 patients), dyspnea (n=58), dizziness (n=38), asthenia (n=37), and chest pain (n=20). All underwent AV nodal ablation and single- (n=39) or dual-chamber (n=25) pacemaker implantation. During follow-up of 20.4 ± 17.8 months, palpitations improved in 100% of 58 patients who had palpitations before the ablation, dyspnea improved in 75% of 58 patients, chest pain in 95% of 20 patients, asthenia in 75% of 37 patients, and dizziness in 93% of 38 patients. Moderate to significant improvement in these symptoms was reported in 83% of patients and mild improvement in 5%. Before ablation, 77% of patients were in New York Heart Association functional class III or IV. After ablation, 19% of patients were in the same functional classes (P<0.05). Thus, AV nodal ablation and pacemaker implantation in patients with drug-refractory atrial fibrillation or flutter was associated with significant improvement in presenting symptoms and functional capacity. A randomized, controlled study is needed to compare this form of therapy with other therapeutic modalities.

Original languageEnglish (US)
Pages (from-to)933-938
Number of pages6
JournalAngiology
Volume48
Issue number11
StatePublished - Nov 1997

Fingerprint

Atrial Flutter
Atrial Fibrillation
Asthenia
Dizziness
Chest Pain
Dyspnea
Pharmaceutical Preparations
Cardiac Arrhythmias

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Symptomatic improvement after AV nodal ablation and pacemaker implantation for refractory atrial fibrillation and atrial flutter. / Kim, Soo G.; Sompalli, Vineel; Rameneni, Anuradha; Gadde, Murali K.; Pamidi, Madhavi; Pathapati, Raja; Ferrick, Kevin J.; Gross, Jay N.; Ben-Zur, Uri; Furman, Seymour; Fisher, John Devens.

In: Angiology, Vol. 48, No. 11, 11.1997, p. 933-938.

Research output: Contribution to journalArticle

Kim, SG, Sompalli, V, Rameneni, A, Gadde, MK, Pamidi, M, Pathapati, R, Ferrick, KJ, Gross, JN, Ben-Zur, U, Furman, S & Fisher, JD 1997, 'Symptomatic improvement after AV nodal ablation and pacemaker implantation for refractory atrial fibrillation and atrial flutter', Angiology, vol. 48, no. 11, pp. 933-938.
Kim, Soo G. ; Sompalli, Vineel ; Rameneni, Anuradha ; Gadde, Murali K. ; Pamidi, Madhavi ; Pathapati, Raja ; Ferrick, Kevin J. ; Gross, Jay N. ; Ben-Zur, Uri ; Furman, Seymour ; Fisher, John Devens. / Symptomatic improvement after AV nodal ablation and pacemaker implantation for refractory atrial fibrillation and atrial flutter. In: Angiology. 1997 ; Vol. 48, No. 11. pp. 933-938.
@article{f081360e93c44b79b8d4d5e082273d0f,
title = "Symptomatic improvement after AV nodal ablation and pacemaker implantation for refractory atrial fibrillation and atrial flutter",
abstract = "Symptomatic Improvement was evaluated in 64 patients with drug- refractory atrial fibrillation or atrial flutter who underwent atrioventricular (AV) nodal ablation and permanent pacemaker implantation. The arrhythmias were chronic in 40 patients and paroxysmal in 24 patients. All were refractory to multiple drugs (3.7 ± 1.5) and had severe symptoms: palpitations (58 patients), dyspnea (n=58), dizziness (n=38), asthenia (n=37), and chest pain (n=20). All underwent AV nodal ablation and single- (n=39) or dual-chamber (n=25) pacemaker implantation. During follow-up of 20.4 ± 17.8 months, palpitations improved in 100{\%} of 58 patients who had palpitations before the ablation, dyspnea improved in 75{\%} of 58 patients, chest pain in 95{\%} of 20 patients, asthenia in 75{\%} of 37 patients, and dizziness in 93{\%} of 38 patients. Moderate to significant improvement in these symptoms was reported in 83{\%} of patients and mild improvement in 5{\%}. Before ablation, 77{\%} of patients were in New York Heart Association functional class III or IV. After ablation, 19{\%} of patients were in the same functional classes (P<0.05). Thus, AV nodal ablation and pacemaker implantation in patients with drug-refractory atrial fibrillation or flutter was associated with significant improvement in presenting symptoms and functional capacity. A randomized, controlled study is needed to compare this form of therapy with other therapeutic modalities.",
author = "Kim, {Soo G.} and Vineel Sompalli and Anuradha Rameneni and Gadde, {Murali K.} and Madhavi Pamidi and Raja Pathapati and Ferrick, {Kevin J.} and Gross, {Jay N.} and Uri Ben-Zur and Seymour Furman and Fisher, {John Devens}",
year = "1997",
month = "11",
language = "English (US)",
volume = "48",
pages = "933--938",
journal = "Angiology",
issn = "0003-3197",
publisher = "SAGE Publications Inc.",
number = "11",

}

TY - JOUR

T1 - Symptomatic improvement after AV nodal ablation and pacemaker implantation for refractory atrial fibrillation and atrial flutter

AU - Kim, Soo G.

AU - Sompalli, Vineel

AU - Rameneni, Anuradha

AU - Gadde, Murali K.

AU - Pamidi, Madhavi

AU - Pathapati, Raja

AU - Ferrick, Kevin J.

AU - Gross, Jay N.

AU - Ben-Zur, Uri

AU - Furman, Seymour

AU - Fisher, John Devens

PY - 1997/11

Y1 - 1997/11

N2 - Symptomatic Improvement was evaluated in 64 patients with drug- refractory atrial fibrillation or atrial flutter who underwent atrioventricular (AV) nodal ablation and permanent pacemaker implantation. The arrhythmias were chronic in 40 patients and paroxysmal in 24 patients. All were refractory to multiple drugs (3.7 ± 1.5) and had severe symptoms: palpitations (58 patients), dyspnea (n=58), dizziness (n=38), asthenia (n=37), and chest pain (n=20). All underwent AV nodal ablation and single- (n=39) or dual-chamber (n=25) pacemaker implantation. During follow-up of 20.4 ± 17.8 months, palpitations improved in 100% of 58 patients who had palpitations before the ablation, dyspnea improved in 75% of 58 patients, chest pain in 95% of 20 patients, asthenia in 75% of 37 patients, and dizziness in 93% of 38 patients. Moderate to significant improvement in these symptoms was reported in 83% of patients and mild improvement in 5%. Before ablation, 77% of patients were in New York Heart Association functional class III or IV. After ablation, 19% of patients were in the same functional classes (P<0.05). Thus, AV nodal ablation and pacemaker implantation in patients with drug-refractory atrial fibrillation or flutter was associated with significant improvement in presenting symptoms and functional capacity. A randomized, controlled study is needed to compare this form of therapy with other therapeutic modalities.

AB - Symptomatic Improvement was evaluated in 64 patients with drug- refractory atrial fibrillation or atrial flutter who underwent atrioventricular (AV) nodal ablation and permanent pacemaker implantation. The arrhythmias were chronic in 40 patients and paroxysmal in 24 patients. All were refractory to multiple drugs (3.7 ± 1.5) and had severe symptoms: palpitations (58 patients), dyspnea (n=58), dizziness (n=38), asthenia (n=37), and chest pain (n=20). All underwent AV nodal ablation and single- (n=39) or dual-chamber (n=25) pacemaker implantation. During follow-up of 20.4 ± 17.8 months, palpitations improved in 100% of 58 patients who had palpitations before the ablation, dyspnea improved in 75% of 58 patients, chest pain in 95% of 20 patients, asthenia in 75% of 37 patients, and dizziness in 93% of 38 patients. Moderate to significant improvement in these symptoms was reported in 83% of patients and mild improvement in 5%. Before ablation, 77% of patients were in New York Heart Association functional class III or IV. After ablation, 19% of patients were in the same functional classes (P<0.05). Thus, AV nodal ablation and pacemaker implantation in patients with drug-refractory atrial fibrillation or flutter was associated with significant improvement in presenting symptoms and functional capacity. A randomized, controlled study is needed to compare this form of therapy with other therapeutic modalities.

UR - http://www.scopus.com/inward/record.url?scp=0030707740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030707740&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 933

EP - 938

JO - Angiology

JF - Angiology

SN - 0003-3197

IS - 11

ER -